Synthesis, in Vitro Bio-evaluation, and Molecular Docking Study of Thiosemicarbazone-based Isatin/bis-Schiff base Hybrid Analogues as Effective Cholinesterase Inhibitors

[1]  Y. Zorlu,et al.  Synthesis and molecular modeling studies of naphthazarin derivatives as novel selective inhibitors of α-glucosidase and α-amylase , 2023, Journal of Molecular Structure.

[2]  R. Hussain,et al.  Synthesis, In Vitro α-Glucosidase Inhibitory Activity and Molecular Docking Study of New Benzotriazole-Based Bis-Schiff Base Derivatives , 2022, Pharmaceuticals.

[3]  R. Hussain,et al.  Synthesis of New Triazole-Based Thiosemicarbazone Derivatives as Anti-Alzheimer’s Disease Candidates: Evidence-Based In Vitro Study , 2022, Molecules.

[4]  W. Dong,et al.  Novel phenoxo-bridged di- and tri-nuclear Cu(II) salamo-like complexes driven by various counter-anions , 2022, Inorganica Chimica Acta.

[5]  R. Hussain,et al.  Benzoxazole based thiazole hybrid analogs: Synthesis, in vitro cholinesterase inhibition, and molecular docking studies , 2022, Computational Toxicology.

[6]  W. Dong,et al.  Solvent-driven self-assembly of two novel di- and tetra-nuclear Cu(II) bis(salamo)-based complexes , 2022, Journal of Molecular Structure.

[7]  W. Dong,et al.  An investigation of two heterobimetallic [Cu(II)2Ln(III)] (Ln = La and Ce) complexes of a more flexible bis(salamo)‐type ligand , 2022, Journal of Molecular Structure.

[8]  R. Hussain,et al.  Molecular iodine-promoted oxidative cyclization for the synthesis of 1,3,4-thiadiazole-fused- [1,2,4]-thiadiazole incorporating 1,4-benzodioxine moiety as potent inhibitors of α-amylase and α-glucosidase: In vitro and in silico study , 2022, Frontiers in Chemistry.

[9]  M. Awad,et al.  Benzimidazole Bearing Thiosemicarbazone Derivatives Act as Potent α-Amylase and α-Glucosidase Inhibitors; Synthesis, Bioactivity Screening and Molecular Docking Study , 2022, Molecules.

[10]  R. Hussain,et al.  New Triazinoindole Bearing Benzimidazole/Benzoxazole Hybrids Analogs as Potent Inhibitors of Urease: Synthesis, In Vitro Analysis and Molecular Docking Studies , 2022, Molecules.

[11]  R. Hussain,et al.  Synthesis of Novel Benzimidazole-Based Thiazole Derivatives as Multipotent Inhibitors of α-Amylase and α-Glucosidase: In Vitro Evaluation along with Molecular Docking Study , 2022, Molecules.

[12]  R. Hussain,et al.  Multipotent Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease: Synthesis, Biological Analysis and Molecular Docking Study of Benzimidazole-Based Thiazole Derivatives , 2022, Molecules.

[13]  R. Hussain,et al.  New biologically potent benzimidazole‐based‐triazole derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors along with molecular docking study , 2022, Journal of Heterocyclic Chemistry.

[14]  N. El‐Metwaly,et al.  Novel organoselenium-based N-mealanilic acid and its zinc (II) chelate: Catalytic, anticancer, antimicrobial, antioxidant, and computational assessments , 2022, Journal of Molecular Liquids.

[15]  N. El‐Metwaly,et al.  Synthesis and Investigation of Bivalent Thiosemicarbazone Complexes: Conformational Analysis, Methyl Green DNA Binding and In-silico Studies , 2022, Arabian Journal for Science and Engineering.

[16]  A. Alrefaei,et al.  Green synthesis for new Co(II), Ni(II), Cu(II) and Cd(II) hydrazone-based complexes; characterization, biological activity and electrical conductance of nano-sized copper sulphate , 2021, Journal of Molecular Structure.

[17]  Tahani M. Bawazeer,et al.  Synthesis and characterization of new thiazole-based Co(II) and Cu(II) complexes; therapeutic function of thiazole towards COVID-19 in comparing to current antivirals in treatment protocol , 2021, Journal of Molecular Structure.

[18]  Razieh Sabet,et al.  Quantitative Structure Activity Relationship of New Isatin Analogues for Design New Compounds as Anti-breast Cancer , 2019, Journal of Pharmaceutical Research International.

[19]  M. Gabr,et al.  Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors. , 2018, Bioorganic chemistry.

[20]  A. Ivanov,et al.  Isatin, an endogenous nonpeptide biofactor: A review of its molecular targets, mechanisms of actions, and their biomedical implications , 2018, BioFactors.

[21]  L. Teh,et al.  Synthesis of azomethines derived from cinnamaldehyde and vanillin: in vitro aetylcholinesterase inhibitory, antioxidant and insilico molecular docking studies , 2018, Medicinal Chemistry Research.

[22]  A. Abdelhamid,et al.  Synthesis and characterization of new pyrazole-based thiazoles , 2017 .

[23]  U. Rashid,et al.  Rational design and synthesis of dihydropyrimidine based dual binding site acetylcholinesterase inhibitors. , 2016, Bioorganic chemistry.

[24]  H. Ullah,et al.  Synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory potential of hydrazide based Schiff bases. , 2016, Bioorganic chemistry.

[25]  L. Teh,et al.  Identification of novel acetylcholinesterase inhibitors: Indolopyrazoline derivatives and molecular docking studies. , 2016, Bioorganic chemistry.

[26]  Qurat-Ul-Ain,et al.  Synthesis, molecular docking, acetylcholinesterase and butyrylcholinesterase inhibitory potential of thiazole analogs as new inhibitors for Alzheimer disease. , 2015, Bioorganic chemistry.

[27]  Mohammad A Kamal,et al.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. , 2014, CNS & neurological disorders drug targets.

[28]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[29]  R. Quirion,et al.  Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies , 2002, Progress in Neurobiology.

[30]  Marsel Mesulam,et al.  Widely Spread Butyrylcholinesterase Can Hydrolyze Acetylcholine in the Normal and Alzheimer Brain , 2002, Neurobiology of Disease.

[31]  J. Mintzer,et al.  Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial , 2001, Journal of neurology, neurosurgery, and psychiatry.

[32]  Xiaoxiang Zhu,et al.  A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase , 2001, Current medical research and opinion.

[33]  D. Melzer.  New drug treatment for Alzheimer's disease: lessons for healthcare policy , 1998, BMJ.

[34]  M. Jann,et al.  Preclinical Pharmacology of Metrifonate , 1998, Pharmacotherapy.

[35]  K. Davis,et al.  The search for disease-modifying treatment for Alzheimer's disease , 1997, Neurology.

[36]  F. Vallette,et al.  Molecular and cellular biology of cholinesterases , 1993, Progress in Neurobiology.

[37]  O. Parsons,et al.  Neuropsychology of dementia. , 1986, Neurologic clinics.

[38]  A. Comeau,et al.  Pseudocholinesterases of mammalian plasma: physicochemical properties and organophosphate inhibition in eleven species. , 1973, Toxicology and applied pharmacology.